CA2914551C - Nanoparticules lipidiques multicompartimentees - Google Patents

Nanoparticules lipidiques multicompartimentees Download PDF

Info

Publication number
CA2914551C
CA2914551C CA2914551A CA2914551A CA2914551C CA 2914551 C CA2914551 C CA 2914551C CA 2914551 A CA2914551 A CA 2914551A CA 2914551 A CA2914551 A CA 2914551A CA 2914551 C CA2914551 C CA 2914551C
Authority
CA
Canada
Prior art keywords
nanoparticles
lipid
hydrophilic
compartment
date received
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2914551A
Other languages
English (en)
French (fr)
Other versions
CA2914551A1 (fr
Inventor
Vincent Faivre
Sylviane Lesieur
Michel Ollivon
Modibo OUATTARA
Tri TRUONG CONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Paris-Saclay
Original Assignee
Centre National de la Recherche Scientifique
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Paris-Sud filed Critical Centre National de la Recherche Scientifique
Publication of CA2914551A1 publication Critical patent/CA2914551A1/fr
Application granted granted Critical
Publication of CA2914551C publication Critical patent/CA2914551C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
CA2914551A 2013-07-25 2014-07-24 Nanoparticules lipidiques multicompartimentees Active CA2914551C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1357363 2013-07-25
FR1357363A FR3008900B1 (fr) 2013-07-25 2013-07-25 Nanoparticules lipidiques multicompartimentees
PCT/FR2014/051922 WO2015011419A1 (fr) 2013-07-25 2014-07-24 Nanoparticules lipidiques multicompartimentées

Publications (2)

Publication Number Publication Date
CA2914551A1 CA2914551A1 (fr) 2015-01-29
CA2914551C true CA2914551C (fr) 2021-05-04

Family

ID=49378477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2914551A Active CA2914551C (fr) 2013-07-25 2014-07-24 Nanoparticules lipidiques multicompartimentees

Country Status (7)

Country Link
US (1) US9757337B2 (enExample)
EP (1) EP3024566B1 (enExample)
JP (1) JP6489556B2 (enExample)
CN (1) CN105408015B (enExample)
CA (1) CA2914551C (enExample)
FR (1) FR3008900B1 (enExample)
WO (1) WO2015011419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017183635A (ja) * 2016-03-31 2017-10-05 ソニー株式会社 半導体装置、半導体装置の製造方法、集積基板、及び、電子機器
US12636384B2 (en) 2019-05-07 2026-05-26 University Health Network Nanoemulsion with porphyrin shell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06183953A (ja) * 1991-06-24 1994-07-05 Nippon Oil & Fats Co Ltd 混合脂質膜小胞
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
HUT75162A (en) * 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
FR2805761B1 (fr) 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
LT2134353T (lt) * 2007-03-30 2017-03-27 Xisle Pharma Ventures Trust Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
CN101687167B (zh) * 2007-07-02 2012-10-03 日清奥利友集团株式会社 W/o/w型乳化组合物
EP2039352A1 (en) * 2007-09-18 2009-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules
CN100558459C (zh) * 2007-12-14 2009-11-11 天津理工大学 以脂质体作为微聚合器制备聚合物微球
CN101366697A (zh) * 2008-08-14 2009-02-18 沈阳万爱普利德医药科技有限公司 一种新的包含紫杉醇类物质的注射用纳米脂质载体及其制备方法

Also Published As

Publication number Publication date
FR3008900B1 (fr) 2018-03-30
WO2015011419A1 (fr) 2015-01-29
JP2016525143A (ja) 2016-08-22
EP3024566A1 (fr) 2016-06-01
FR3008900A1 (fr) 2015-01-30
US20160158153A1 (en) 2016-06-09
US9757337B2 (en) 2017-09-12
JP6489556B2 (ja) 2019-03-27
CA2914551A1 (fr) 2015-01-29
CN105408015B (zh) 2019-03-12
CN105408015A (zh) 2016-03-16
EP3024566B1 (fr) 2019-05-01

Similar Documents

Publication Publication Date Title
Gómez-Mascaraque et al. Microencapsulation structures based on protein-coated liposomes obtained through electrospraying for the stabilization and improved bioaccessibility of curcumin
EP2129455B1 (fr) Procédé de préparation de nano-émulsions
CA2557755C (fr) Procede de preparation de microspheres biodegradables calibrees
CA2513781C (fr) Systemes pour microencapsulation et leurs applications
FR2852843A1 (fr) Systeme galenique permettant le masquage du gout
EP2376218A1 (fr) Procede de preparation de nanoparticules lipidiques
Chen et al. Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility
Lindner et al. Optimizing hydrophilic drug incorporation into SEDDS using dry reverse micelles: a comparative study of preparation methods
EP3033110A1 (fr) Nouveau systeme solide instantane auto-emulsionnant a base de cyclodextrines et d'huile (s) pour l'administration orale
EP3024566B1 (fr) Nanoparticules lipidiques multicompartimentées
EP3432729B1 (fr) Nanocapsules de principe actif liposoluble, fabrication et utilisations
WO1998056352A1 (fr) Nouveaux vecteurs liposomaux de principes actifs
CA2541009C (fr) Compositions de particules lipidiques solides monodisperses
EP1162950B1 (fr) Milieux sous forme de dispersions complexes, leur procede de preparation et leurs utilisations
Alshehri et al. Flufenamic acid-loaded self-nanoemulsifying drug delivery system for oral delivery: from formulation statistical optimization to preclinical anti-inflammatory assessment
EP3887011B1 (fr) Procédé d'extraction de substances d'intérêt
WO2001049264A2 (fr) Compositions pharmaceutiques destinees a une administration par voie orale
Chotaliya et al. Development of Ivabradine Hydrochloride Nanosuspension Containing Gel for Transdermal Delivery: In Vitro and Ex Vivo Characterization
JP2016525143A5 (enExample)
FR2939698A1 (fr) Procede de fabrication d'une formulation et utilisation pour la delivrance de medicaments polaires
WO2007000531A2 (fr) Procede de preparation de particules lipidiques solides, mettant en oeuvre un reacteur membranaire
조민제 Microfluidic assembly of lipid nano-vesicles (liposomes and niosomes): investigation on membrane fluidity and stability by surface modifications
FR2868951A1 (fr) Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation
WO2005030170A2 (fr) Rupture controlee de liposomes furtifs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190327

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250716

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250716

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260722